![](https://media.npr.org/assets/img/2023/04/19/mifecloseup_wide-395213f3aec5e246437c37dc0d158bc2474c1485-s1100-c50.jpg)
The drug producer GenBioPro obtained FDA approval for its generic model of the abortion tablet mifepristone — the primary dose in a widely-used, two-drug protocol — in 2019.
Sarah McCammon/NPR
cover caption
toggle caption
Sarah McCammon/NPR
![](https://media.npr.org/assets/img/2023/04/19/mifecloseup_wide-395213f3aec5e246437c37dc0d158bc2474c1485-s1200.jpg)
The drug producer GenBioPro obtained FDA approval for its generic model of the abortion tablet mifepristone — the primary dose in a widely-used, two-drug protocol — in 2019.
Sarah McCammon/NPR
The producer of a generic type of the abortion tablet mifepristone is suing the Meals and Drug Administration in an effort to protect entry as federal litigation the FDA’s approval of the drug.
In a federal lawsuit filed at present in Maryland, drug producer GenBioPro asks a decide to ban the FDA from taking any motion that may disrupt entry to the tablets. GenBioPro says revoking the FDA approval of generic mifepristone would trigger “catastrophic hurt” to the corporate, and to docs and sufferers who depend on the drug.
Mifepristone was first accredited in 2000 as the primary dose in a widely-used, two-drug protocol accredited to induce some first trimester abortions. GenBioPro obtained FDA approval for its in 2019.
Anti-abortion rights teams are difficult each the FDA’s authentic 2000 determination and later rule adjustments, together with the generic drug approval in 2019.
A from the U.S. Supreme Court docket preserving status-quo entry to mifepristone expires at 11:59 p.m. ET at present until the court docket intervenes. If the keep expires, an order from the fifth U.S. Circuit Court docket of Appeals would take impact and impose , together with prohibiting the tablets from being distributed by mail.